Risk Warning & Pitfall Avoidance: Glucagon Side Effects in Peptide Product Composition
Title: Risk Warning & Pitfall Avoidance: Glucagon Side Effects in Peptide Product Composition Abstract: Glucagon, a critical peptide in metabolic regulation, presents significant side effects (e.g., nausea, hypoglycemia rebound) when improperly formulated in multi-component products. Current market trends show a 12.4% CAGR (2024-2030) for therapeutic peptides, yet brand differentiation hinges on purity (>98% HPLC) and excipient compatibility. Comparative analysis reveals that GMP-certified manufacturers (e.g., Bachem, Novo Nordisk) outperform generic suppliers in stability and batch consistency. Key pitfalls include mislabeling of glucagon-like analogs and inadequate cold-chain logistics (-20°C), which degrade efficacy. For safe selection, prioritize third-party COAs, avoid blends with unverified synergies, and verify factory ISO 13485 accreditation.